Abstracts tagged "autoantibodies and plasma cells"

Abstract Number: 2792 • 2018 ACR/ARHP Annual Meeting
The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus
Laura van Dam¹, Zgjim Osmani¹, Tineke Kraaij¹, Sylvia W.A. Kamerling¹, Jaap A. Bakker², Hans U. Scherer³, Ton Rabelink¹, Reinhard Voll⁴, David A. Isenberg⁵, Cees van Kooten¹ and Y.K. Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁵University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a severe systemic autoimmune disease characterized by immune-complexes (ICx) which cause inflammation and damage. Effective targeting of autoantibody secreting…
Abstract Number: 25 • 2013 ACR/ARHP Annual Meeting
SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses
H. Travis Ichikawa, Medicine, Emory University, Atlanta, GA
Background/Purpose: Increased circulating antibody secreting cells (ASC), including both CD138- plasmablasts and CD138+ plasma cells (PB/PC), correlate with SLE activity and are prominent during Lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].